38692-80-7

Basic information

• Product Name: 3-BROMO-4-HYDROXYPHENYLACETIC ACID
• Synonyms: 3-BROMO-4-HYDROXYBENZENEACETIC ACID;3-BROMO-4-HYDROXYPHENYLACETIC ACID;3-Bromo-4-hydroxyphenyl;2-(3-bromo-4-hydroxyphenyl)acetic acid
• CAS NO: 38692-80-7
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• EINECS: 254-089-8
• Product Categories: Aromatic Phenylacetic Acids and Derivatives;Organic acids
• Mol File: 38692-80-7.mol

Chemical Properties

• Melting Point: 105-107℃
• Boiling Point: 364℃
• Flash Point: 174℃
• Appearance: /
• Density: 1.757
• Vapor Pressure: 6.18E-06mmHg at 25°C
• Refractive Index: 1.632
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.33±0.10(Predicted)
• CAS DataBase Reference: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(38692-80-7)
• EPA Substance Registry System: 3-BROMO-4-HYDROXYPHENYLACETIC ACID(38692-80-7)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• HazardClass: IRRITANT
• Hazardous Substances Data: 38692-80-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Bromo-4-hydroxyphenylacetic acid is used as a key building block in the synthesis of various pharmaceuticals. Its unique structure, including the bromine and hydroxyl groups, allows for the development of new drugs with potential therapeutic benefits.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-Bromo-4-hydroxyphenylacetic acid is utilized for research purposes. Its properties and reactivity make it a valuable compound for exploring new drug candidates and understanding the structure-activity relationships in drug design.
Used in Drug Development for Therapeutic Purposes:
3-Bromo-4-hydroxyphenylacetic acid has potential applications in the development of drugs for various therapeutic purposes. Its presence in the synthesis of pharmaceuticals can contribute to the creation of novel treatments for a range of medical conditions, enhancing the scope of available medications.

InChI:InChI=1/C8H7BrO3/c9-6-3-5(4-8(11)12)1-2-7(6)10/h1-3,10H,4H2,(H,11,12)

Upstream product

• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 95-56-7 2-hydroxybromobenzene 
• 74270-54-5 4-hydroxy-3-bromomandelic acid 
• 156-38-7 4-hydroxyphenylacetate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 

Downstream Products

• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 19626-36-9 methyl 2-(3-bromo-4-methoxyphenyl)acetate 
• 29121-25-3 ethyl 2-(3-bromo-4-hydroxyphenyl)acetate 
• 124840-59-1 4-Benzyloxy-3-brom-phenylessigsaeure-benzylester 
• 774-81-2 (3-bromo-4-methoxy-phenyl)-acetic acid 
• 5884-61-7 (4-hydroxy-3,4'-oxy-diphenyl)-di-acetic acid 
• 42583-41-5 2-{4-[5-(carboxymethyl)-2-methoxyphenoxy]phenyl}acetic acid 
• 655237-87-9 1-(3-bromo-4-hydroxyphenyl)-acetone 
• 303012-68-2 1-(2,4,6-trihydroxyphenyl)-2-(3-bromo-4-hydroxyphenyl)ethanone 
• 1201916-20-2 C₁₈H₁₇BrN₂O₂ 
• 1201916-22-4 C₁₈H₁₆Br₂N₂O₂ 
• 1258845-78-1 3-[2-(3-bromo-4-hydroxyphenyl)acetamido]-2-(4-tertbutylbenzyl)propyl pivalate 
• 1254646-35-9 2-[4-hydroxy-3-pentylphenyl]acetic acid 
• 1391574-01-8 benzyl (E)-2-[4-benzyloxy-3-[pent-1-enyl]phenyl]acetate 

Relevant articles and documents

Novel total synthesis method of racemic tetrandrine

The invention discloses a novel total synthesis method of racemic tetrandrine, and belongs to the technical field of pharmaceutical chemical synthesis. 5-bromovanillin and 4-hydroxyphenylacetic acid which are low in price and easy to obtain are respectively used as starting materials to synthesize a compound 10, the compound 10 is used for synthesizing a compound 12 and a compound 14 through a simple route, and the two compounds are subjected to intermolecular and intramolecular Ullmann reaction to synthesize the racemic tetrandrine A. The key intermediates 12 and 14 are synthesized through the compound 10, the synthesis efficiency is greatly improved, the raw materials are utilized to the maximum extent, and the method is a racemic tetrandrine total synthesis route which is simplest in operation and lowest in cost so far.

Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin

As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3- methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I > Br > Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with Ki (ant) = 2.77 and 2.19 nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6′-iodononivamide.

N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

2-'5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.

2- [5- (5-carbamimidoyl-1H-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors

The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders. Processes for preparing these inhibitors are also disclosed.

Synthesis and Properties of Optically Active Phenoxypropionates. Effect of Halogeno Substituent in the Core on Physical Properties

Chiral phenoxypropionates having halogenated 2,5-diphenylpyrimidine cores were synthesized and the effect of a halogeno-substituent on the physical properties such as mesomorphic behavior, spontaneous polarization (Ps) and response time (τ) were investigated.The introduction of a halogen atom to the phenyl ring of 2,5-diphenylpyrimidine core led to a decrease in the thermal stability of mesophases.The Ps values in the achiral host liquid crystal mixture were increased by introducing the halogen atom.However, response times were not improved. - Keywords: ferroelectric liquid crystal, phenoxypropionate, halogeno-substituent

On the Synthesis of Tiliacora Alkaloids, II: Synthesis of the Asymmetrical Biphenyl Derivative

The biphenyl derivatives S-1 and S-3 were obtained by mixed Ullmann reaction of the phenylacetic esters 3, 4 and 5.Because they contain selectively removable protective groups for the carboxyl functions, S-1 and S-3 are proper intermediates for the constitution selective reaction with the former described asymmetrical dibenzo-1,4-dioxin derivative K.